{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T12:27:30Z","timestamp":1710851250905},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Recurrent\/refractory hematologic malignancies have a poor prognosis, and there is a need for novel treatment regimens that can be tolerated by this heavily pretreated patient group. Clofarabine has antileukemic activity with an acceptable toxicity profile. In a phase I clinical trial (NCT00824135), we substituted clofarabine for fludarabine in a well-established reduced-intensity conditioning regimen for a T cell\u2013depleted, mismatched-related (haploidentical) donor transplant backbone and explored the maximum tolerated dose of clofarabine in this combination in 15 patients undergoing hematopoietic cell transplantation for recurrent\/refractory or secondary leukemia. Clofarabine was well tolerated at a dose of 50\u2009mg\/m<jats:sup>2<\/jats:sup>\/d for 5 days in this regimen, with minimal treatment-related mortality in a heavily pretreated group of high-risk patients. All patients exhibited quick hematopoietic recovery, with median times to neutrophil and platelet engraftment being 11 and 16 days, respectively. Transient elevation of transaminases was the most common toxicity\u2014observed in 13 patients (86.7%), with 6 (40%) grade III or above. Three patients (20%) developed hepatic veno-occlusive disease. Eleven patients (73.3%) died, with the most common cause of death being disease relapse (in 9 patients [60%]), followed by treatment-related mortality (in 2 patients [13.3%]). Four (26.6%) of the patients are long-term survivors.<\/jats:p>","DOI":"10.1097\/mph.0000000000001222","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T21:57:04Z","timestamp":1525989424000},"page":"e479-e485","source":"Crossref","is-referenced-by-count":3,"title":["Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms"],"prefix":"10.1097","volume":"40","author":[{"given":"Akshay","family":"Sharma","sequence":"first","affiliation":[{"name":"Oncology"},{"name":"Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guolian","family":"Kang","sequence":"additional","affiliation":[{"name":"Biostatistics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anusha","family":"Sunkara","sequence":"additional","affiliation":[{"name":"Biostatistics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Inaba","sequence":"additional","affiliation":[{"name":"Oncology"},{"name":"Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sima","family":"Jeha","sequence":"additional","affiliation":[{"name":"Oncology"},{"name":"Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane J.","family":"Cross","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrence","family":"Geiger","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Triplett","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant and Cellular Therapy, St Jude Children\u2019s Research Hospital"},{"name":"Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3109\/10428194.2012.741230","article-title":"Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia","volume":"54","author":"Devillier","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.bbmt.2007.06.007","article-title":"Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation","volume":"13","author":"Mielcarek","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2013.09.011","article-title":"Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Thanarajasingam","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/bmt.2012.29","article-title":"Second allogeneic hematopoietic SCT for relapsed ALL in children","volume":"47","author":"Kato","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bbmt.2006.09.005","article-title":"Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience","volume":"13","author":"Arellano","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/cncr.20743","article-title":"Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia","volume":"103","author":"Rivera","year":"2005","journal-title":"Cancer"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2141.2001.02647.x","article-title":"Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin\u2019s lymphoma treated with the UKCCSG 9003\/9002 protocols","volume":"112","author":"Atra","year":"2001","journal-title":"Br J Haematol"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.bmt.1702373","article-title":"Poor outcome in children with refractory\/relapsed leukemia undergoing bone marrow transplantation with mismatched family member donors","volume":"25","author":"Goldman","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1200\/JCO.2001.19.16.3675","article-title":"Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation","volume":"19","author":"Bosi","year":"2001","journal-title":"J Clin Oncol"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/sj.bmt.1700680","article-title":"Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes","volume":"19","author":"Kishi","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.1365-2141.2000.01851.x","article-title":"Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de moelle (SFGM)","volume":"108","author":"Michallet","year":"2000","journal-title":"Br J Haematol"},{"key":"R13-20230918","first-page":"269","article-title":"Second HLA-identical sibling transplants for leukemia recurrence","volume":"9","author":"Mrsic","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bmt.2015.186","article-title":"Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT","volume":"50","author":"Ruutu","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000253025","article-title":"Second allogeneic stem cell transplantation in myeloid malignancies","volume":"122","author":"Hartwig","year":"2009","journal-title":"Acta Haematol"},{"key":"R16-20230918","first-page":"331","article-title":"Second allogeneic hematopoietic stem cell transplantation in hematologic malignancies in children: long-term results of a multicenter study of the Spanish Working Party for Bone Marrow Transplantation in Children (GETMON)","volume":"87","author":"Mu\u00f1oz","year":"2002","journal-title":"Haematologica"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","article-title":"Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia","volume":"102","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/bjh.13437","article-title":"A phase I\/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age","volume":"170","author":"Buckley","year":"2015","journal-title":"Br J Haematol"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/cncr.28674","article-title":"AAML0523: a report from the Children\u2019s Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia","volume":"120","author":"Cooper","year":"2014","journal-title":"Cancer"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/blood-2013-04-496596","article-title":"Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival","volume":"122","author":"Burnett","year":"2013","journal-title":"Blood"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.clml.2015.11.016","article-title":"Clofarabine plus low-dose cytarabine is as effective as and less toxic than intensive chemotherapy in elderly AML patients","volume":"16","author":"Takahashi","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nrd2055","article-title":"Discovery and development of clofarabine: a nucleoside analogue for treating cancer","volume":"5","author":"Bonate","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/MPH.0b013e31820fee1d","article-title":"Institutional experience with clofarabine and cytarabine in relapsed pediatric acute myeloid leukemia","volume":"34","author":"Moreno","year":"2012","journal-title":"J Pediatr Hematol Oncol"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/eci.12294","article-title":"Clofarabine\/cyclophosphamide for debulking before stem cell transplantation","volume":"44","author":"Rabitsch","year":"2014","journal-title":"Eur J Clin Invest"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clml.2013.12.001","article-title":"Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"14","author":"Faderl","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/pbc.24264","article-title":"Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias","volume":"59","author":"Abd Elmoneim","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2003-06-2122","article-title":"Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia","volume":"103","author":"Jeha","year":"2004","journal-title":"Blood"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/leu.2010.319","article-title":"Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia","volume":"25","author":"Farag","year":"2011","journal-title":"Leukemia"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.bbmt.2011.10.041","article-title":"Phase I\u2013II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation","volume":"18","author":"van Besien","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R31-20230918","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"R32-20230918","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2307\/2531693","article-title":"Design and analysis of phase I clinical trials","volume":"45","author":"Storer","year":"1989","journal-title":"Biometrics"},{"key":"R34-20230918","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/bmt.2012.196","article-title":"Fludarabine-induced severe necrotizing leukoencephalopathy in pediatric hematopoietic cell transplantation","volume":"48","author":"Helton","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"R35-20230918","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1182\/asheducation-2009.1.414","article-title":"ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse?","volume":"1","author":"Thakar","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R36-20230918","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.bbmt.2016.05.001","article-title":"Second allogeneic stem cell transplantation for acute leukemia using a chemotherapy-only cytoreduction with clofarabine, melphalan, and thiotepa","volume":"22","author":"Spitzer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R37-20230918","first-page":"2386","article-title":"Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5\u2019-triphosphate","volume":"51","author":"Parker","year":"1991","journal-title":"Cancer Res"},{"key":"R38-20230918","first-page":"3030","article-title":"Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine","volume":"56","author":"Xie","year":"1996","journal-title":"Cancer Res"},{"key":"R39-20230918","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1182\/blood.V96.10.3537","article-title":"Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria","volume":"96","author":"Genini","year":"2000","journal-title":"Blood"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201811000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:09:48Z","timestamp":1695010188000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201811000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001222","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}